FMP

FMP

Enter

FSTX - F-star Therapeutics,...

photo-url-https://images.financialmodelingprep.com/symbol/FSTX.png

F-star Therapeutics, Inc.

FSTX

NASDAQ

Inactive Equity

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

7.12 USD

0 (0%)

About

ceo

Dr. Eliot Richard Forster M.B.A., Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

CIK

0001566373

ISIN

US30315R1077

CUSIP

30315R107

Address

Eddeva B920

Phone

44 1223 497400

Country

GB

Employee

84

IPO Date

May 6, 2016

Key Executives

Name

Title

Pay

Year Born

Mr. James Sandy MPhil

Chief Devel. Officer

0

N/A

Ms. Darlene M. Deptula-Hicks MBA

Chief Financial Officer, Treasurer & Sec...

739.69k

1957

Dr. Eliot Richard Forster M.B.A., Ph.D.

Pres, Chief Executive Officer & Director

866.02k

1966

Lindsey Trickett

Vice President of Investor Relations & C...

0

N/A

Dr. Neil Brewis Ph.d.

Chief Scientific Officer

557.36k

1967

Dr. Louis Kayitalire M.D.

Chief Medical Officer

612.74k

1958

As of December 31, 2024, the total employee count stands at 84, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep